Probiodrug and Crossbeta Extend Alzheimer’s Biomarker Partnership

Probiodrug and Crossbeta Extend Alzheimer’s Biomarker Partnership
Probiodrug and Crossbeta Biosciences are extending a partnership that Probiodrug believes will help it continue developing a potential Alzheimer’s therapy. Under the partnership, established in 2016, the companies are using a proprietary Crossbeta technology to try to create biomarkers specific to Alzheimer’s as opposed to   neurodegenerative diseases in general. Biomarkers are substances that can detect and help diagnosis

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *